Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL1B | P01584 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384927 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16569284 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18546682 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15559912 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22827076 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL17277066 | 0.89 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20548448 | 0.89 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2381757 | 0.88 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2381765 | 0.88 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29636257 | 0.88 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118908940-B | Preparation and application of target anti-apoptosis Bcl-2 proteolytic targeting chimeric | 齐鲁理工学院 | 2024-12-31 | — | — | CN | claimed |
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-115745979-A | Protein targeted degradation compound and application thereof | 中国医学科学院医药生物技术研究所 | 2023-03-07 | — | — | CN | claimed |
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-118908940-B | Preparation and application of target anti-apoptosis Bcl-2 proteolytic targeting chimeric | 齐鲁理工学院 | 2024-12-31 | — | — | CN | disclosed |
| CN-118908940-A | Preparation and application of target anti-apoptosis Bcl-2 proteolytic targeting chimeric | 齐鲁理工学院 | 2024-11-08 | — | — | CN | disclosed |
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-116490184-A | Compounds for inhibiting EGFR mutant cancers and pharmaceutical uses thereof | J2H生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-115745979-A | Protein targeted degradation compound and application thereof | 中国医学科学院医药生物技术研究所 | 2023-03-07 | — | — | CN | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-115043817-A | SOS1 proteolysis regulator and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114945569-A | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same | 延世大学校产学协力团 | 2022-08-26 | — | — | CN | disclosed |
| CN-114286678-A | Compounds for inhibiting and inducing degradation of EGFR and ALK | 北京泰德制药股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | CDK2, SKP2, CDK5 | DDB1 438/4885CRBN 307/4885IKZF3 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.